Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00483860 · ClinicalTrials.gov registry record · Phase 1

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
59
Enrollment target

NCT00483860 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 59 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00483860, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
59 participants
Enrollment target

Study Summary

To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally

Interventions

  • DRUG Topotecan

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2007-06-20
Est. Completion 2012-02-06
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00483860

The ClinicalTrials.gov registry entry for NCT00483860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Topotecan is the first listed.

NCT00483860 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00483860 about?

NCT00483860 is a clinical study titled "A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function". To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally

What is the current status of trial NCT00483860?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2007-06-20. Estimated completion is 2012-02-06.

What interventions are being tested in trial NCT00483860?

The interventions under investigation include: Topotecan (DRUG).

Who is sponsoring clinical trial NCT00483860?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.